Evidence map›Paper›PMID 24129437›Full record

ArticleEuropean journal of human genetics : EJHG2014

Early-onset obesity and paternal 2pter deletion encompassing the ACP1, TMEM18, and MYT1L genes.

Martine Doco-Fenzy, Camille Leroy, Anouck Schneider, Florence Petit, Marie-Ange Delrue, Joris Andrieux, Laurence Perrin-Sabourin, Emilie Landais, Azzedine Aboura, Jacques Puechberty and 14 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02980302 (Development of the Tool " iPSC "), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02980302 nacompletednot on this mapstarted 2015, after this paper: background citation

Development of the Tool " iPSC " (Induced Pluripotent Stem Cells) for the Functional Study of Mutations Responsible for Mental Retardation - Application to Familial Study of MYT1L Gene Mutations

TypeinterventionalSponsorUniversity Hospital, GrenobleRan2015 to 2017Enrolled4ConditionsIntellectual Deficiency, Asymptomatic Carrier of the Mutation of the Gene MYT1L, Healthy VolunteersArmsCutaneous biopsy
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. MYT1L: A systematic review of genetic variation encompassing schizophrenia and autism.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2020
    Pooled it
  2. Neurobehavioral Profiles and Clinical Consequences ofmedRxiv : the preprint server for health sciences · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Understanding the Role of lncRNAs in Nervous System Development.Advances in experimental medicine and biology · 2017
    Review
  14. Genetics of Prader-Willi syndrome and Prader-Will-Like syndrome.Annals of pediatric endocrinology & metabolism · 2016
    Review
  15. Article
  16. Article
  17. Article
  18. Haploinsufficiency of the MYT1L gene causes intellectual disability frequently associated with behavioral disorder.Genetics in medicine : official journal of the American College of Medical Genetics · 2015
    Article
  19. Article
  20. Refinement of the critical 2p25.3 deletion region: the role of MYT1L in intellectual disability and obesity.Genetics in medicine : official journal of the American College of Medical Genetics · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 1 country.

Martine Doco-FenzyService de Génétique, Hôpital Maison-Blanche, CHRU, UFR de Médecine, Reims, France.
Camille LeroyService de Génétique, Hôpital Maison-Blanche, CHRU, UFR de Médecine, Reims, France.
Anouck SchneiderDépartement de Génétique Médicale, CHRU Montpellier, Faculté de Médecine de Montpellier-Nimes, Université Montpellier 1, Montpellier, France.
Florence PetitService de Génétique, CHU de Lille, Lille, France.
Marie-Ange DelrueService de Génétique Médicale, Laboratoire MRGM, (EA 4576), CHRU de Bordeaux, Bordeaux, France.
Joris AndrieuxService de Génétique, CHU de Lille, Lille, France.
Laurence Perrin-SabourinFédération de Génétique, Hopital Robert Debré, APHP Paris, Paris, France.
Emilie LandaisService de Génétique, Hôpital Maison-Blanche, CHRU, UFR de Médecine, Reims, France.
Azzedine AbouraFédération de Génétique, Hopital Robert Debré, APHP Paris, Paris, France.
Jacques Puechberty1] Département de Génétique Médicale, CHRU Montpellier, Faculté de Médecine de Montpellier-Nimes, Université Montpellier 1, Montpellier, France [2] Plateforme puce à ADN, CHRU Montpellier, Université Montpellier 1, Montpellier, France.
Manon GirardPlateforme puce à ADN, CHRU Montpellier, Université Montpellier 1, Montpellier, France.
Magali TournairePlateforme puce à ADN, CHRU Montpellier, Université Montpellier 1, Montpellier, France.
Elodie SanchezDépartement de Génétique Médicale, CHRU Montpellier, Faculté de Médecine de Montpellier-Nimes, Université Montpellier 1, Montpellier, France.
Caroline RooryckService de Génétique Médicale, Laboratoire MRGM, (EA 4576), CHRU de Bordeaux, Bordeaux, France.
Agnès AmeilService de Pédiatrie, American Memorial Hospital, CHRU, Reims, France.
Michel GoossensLaboratoire de Génétique, AP-HP, et INSERM U-841, CHU Henri Mondor, Créteil, France.
Philippe JonveauxService de Génétique, CHRU de Nancy-Brabois, Inserm U954, Université de Lorraine, Nancy, France.
Geneviève Lefort1] Département de Génétique Médicale, CHRU Montpellier, Faculté de Médecine de Montpellier-Nimes, Université Montpellier 1, Montpellier, France [2] Plateforme puce à ADN, CHRU Montpellier, Université Montpellier 1, Montpellier, France.
Laurence TaineService de Génétique Médicale, Laboratoire MRGM, (EA 4576), CHRU de Bordeaux, Bordeaux, France.
Dorothée CailleyService de Génétique Médicale, Laboratoire MRGM, (EA 4576), CHRU de Bordeaux, Bordeaux, France.
Dominique GaillardService de Génétique, Hôpital Maison-Blanche, CHRU, UFR de Médecine, Reims, France.
Bruno LeheupCHU de Nancy, Pole Enfant, Service de génétique clinique, Vandoeuvre les nancy, F-54511, France.
Pierre SardaDépartement de Génétique Médicale, CHRU Montpellier, Faculté de Médecine de Montpellier-Nimes, Université Montpellier 1, Montpellier, France.
David GenevièveDépartement de Génétique Médicale, CHRU Montpellier, Faculté de Médecine de Montpellier-Nimes, Université Montpellier 1, Montpellier, France.
Université de Montpellier · FRCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Reims · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Lille · FRInserm · FRCentre Hospitalier Régional et Universitaire de Nancy · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is a common but highly, clinically, and genetically heterogeneous disease. Deletion of the terminal region of the short arm of chromosome 2 is rare and has been reported in about 13 patients in the literature often associated with a Prader-Willi-like phenotype. We report on five unrelated patients with 2p25 deletion of paternal origin presenting with early-onset obesity, hyperphagia, intellectual deficiency, and behavioural difficulties. Among these patients, three had de novo pure 2pter deletions, one presented with a paternal derivative der(2)t(2;15)(p25.3;q26) with deletion in the 2pter region and the last patient presented with an interstitial 2p25 deletion. The size of the deletions was characterized by SNP array or array-CGH and was confirmed by fluorescence in situ hybridization (FISH) studies. Four patients shared a 2p25.3 deletion with a minimal critical region estimated at 1.97 Mb and encompassing seven genes, namely SH3HYL1, ACP1, TMEMI8, SNTG2, TPO, PXDN, and MYT1L genes. The fifth patient had a smaller interstitial deletion encompassing the TPO, PXDN, and MYT1L genes. Paternal origin of the deletion was determined by genotyping using microsatellite markers. Analysis of the genes encompassed in the deleted region led us to speculate that the ACP1, TMEM18, and/or MYT1L genes might be involved in early-onset obesity. In addition, intellectual deficiency and behavioural troubles can be explained by the heterozygous loss of the SNTG2 and MYT1L genes. Finally, we discuss the parent-of-origin of the deletion.

Indexed as

Sequence DeletionChildChild, PreschoolChromosomes, Human, Pair 2Comparative Genomic HybridizationFemaleGenome-Wide Association StudyGenotypeHumansIn Situ Hybridization, FluorescenceMaleMembrane ProteinsNerve Tissue ProteinsObesityPhenotypePolymorphism, Single NucleotideACP1 protein, humanMembrane ProteinsMYT1L protein, humanNerve Tissue ProteinsProtein Tyrosine PhosphatasesProto-Oncogene ProteinsTMEM18 protein, humanTranscription Factors

Identifiers

PMID24129437
PMCPMC3953915
OpenAlexW2029150726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.